title: An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir.
abstract: We have developed a recombinant Escherichia coli screening system for the rapid detection and identification of amino acid substitutions in the human immunodeficiency virus (HIV) protease associated with decreased susceptibility to the protease inhibitor indinavir (MK-639; Merck & Co.). The assay depends upon the correct processing of a segment of the HIV-1 HXB2 gag-pol polyprotein followed by detection of HIV reverse transcriptase activity by a highly sensitive, colorimetric enzyme-linked immunosorbent assay. The highly sensitive system detects the contributions of single substitutions such as I84V, L90M, and L63P. The combination of single substitutions further decreases the sensitivity to indinavir. We constructed a library of HIV protease variant genes containing dispersed mutations and, using the E. coli recombinant system, screened for mutants with decreased indinavir sensitivity. The discovered HIV protease variants contain amino acid substitutions commonly associated with indinavir resistance in clinical isolates, including the substitutions L90M, L63P, I64V, V82A, L24I, and I54T. One substitution, W6R, is also frequently found by the screen and has not been reported elsewhere. Of a total of 12,000 isolates that were screened, 12 protease variants with decreased sensitivity to indinavir were found. The L63P substitution, which is also associated with indinavir resistance, increases the stability of the isolated protease relative to that of the native HXB2 protease. The rapidity, sensitivity, and accuracy of this screen also make it useful for screening for novel inhibitors. We have found the approach described here to be useful for the detection of amino acid substitutions in HIV protease that have been associated with drug resistance as well as for the screening of novel compounds for inhibitory activity.
authors.affiliation: Sepracor Inc., Marlborough, Massachusetts 01752, USA. lmelnick@sepracor.com
authors.forename: L
authors.initials: L
authors.lastname: Melnick
authors.forename: S S
authors.initials: SS
authors.lastname: Yang
authors.forename: R
authors.initials: R
authors.lastname: Rossi
authors.forename: C
authors.initials: C
authors.lastname: Zepp
authors.forename: D
authors.initials: D
authors.lastname: Heefner
mesh_terms: D019943:Amino Acid Substitution; D015153:Blotting, Western; D004352:Drug Resistance, Microbial; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism*; D015723:Gene Library; D005838:Genotype; D016333:HIV Protease / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics / Q000302:isolation & purification; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D054303:HIV Reverse Transcriptase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D019469:Indinavir / Q000494:pharmacology*; D016297:Mutagenesis, Site-Directed; D010957:Plasmids
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir; D054303:HIV Reverse Transcriptase; D016333:HIV Protease